Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | YAP1 | P46937 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22043521 | 0.89 | ALOX15 (0.48) | ALOX15CNR2EPHX2EPHX1MEN1 | |
| SCHEMBL22043545 | 0.89 | ALOX15 (0.48) | ALOX15CNR2EPHX2EPHX1MEN1 | |
| SCHEMBL22043531 | 0.84 | ALOX15 (0.67) | ALOX15HDAC8CNR2EPHX2EPHX1 | |
| SCHEMBL22043546 | 0.84 | ALOX15 (0.67) | ALOX15HDAC8CNR2EPHX2EPHX1 | |
| SCHEMBL22043539 | 0.81 | ALOX15 (0.70) | ALOX15CNR2EPHX2MEN1KMT2A | |
| SCHEMBL22043538 | 0.78 | CNR2 (0.37) | ALOX15HDAC8CNR2EPHX2EPHX1 | |
| SCHEMBL23873653 | 0.76 | ALOX15 (0.50) | ALOX15HDAC8CNR2EPHX2EPHX1 | |
| SCHEMBL22043520 | 0.72 | ALOX15 (0.50) | ALOX15HDAC8EPHX2YAP1 | |
| SCHEMBL16579940 | 0.71 | ALOX15 (0.55) | ALOX15HDAC8MEN1KMT2AYAP1 | |
| SCHEMBL32660002 | 0.70 | ALOX15 (0.54) | ALOX15HDAC8EPHX2YAP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156790-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-05-16 | — | — | US | disclosed |
| US-20210299107-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-09-30 | — | — | US | disclosed |
| WO-2020113028-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156790-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | AIFM2, GPX1, SLC7A11 | ALOX15 286/4885HDAC8 653/4885CNR2 2260/4885 |
| US-20210299107-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | AIFM2, GPX1, SLC7A11 | ALOX15 286/4885HDAC8 653/4885CNR2 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.